Minor
Suspected
描述
Rosuvastatin and colchicine share BCRP transporter-mediated elimination; colchicine may weakly increase rosuvastatin exposure, and both carry myotoxic potential that could be additive.
机制
Rosuvastatin is a substrate of BCRP (ABCG2) and OATP1B1/1B3; colchicine inhibits BCRP to a minor degree, potentially raising rosuvastatin AUC slightly; additive myopathy risk from two agents with muscle toxicity profiles.
临床意义
The OATP/BCRP interaction is modest with colchicine; muscle toxicity cases have been reported for colchicine-statin combinations, although predominantly with CYP3A4-metabolised statins.
处理措施
No routine dose adjustment is required; counsel patients to report muscle symptoms; measure CK if myopathy is suspected.